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Research Aims
• Does mast cell infiltration change under a MCD 
induced NASH model? 
• Does CBG treatment help reduce mast cell 
infiltration? 
Hypothesis: Mast cell infiltration will increase 
under the MCD diet and low CBG treatment will 
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Mast Cell Infiltration in Control vs MCD Livers 
Figure one. Results from the CAE staining of paraffin slides. Liver samples were from female mice. 
Arrows point to mast cells found within the hepatic tissue. No mast cells were observed in the CTR 
group, and the highest mast cell counts were observed in the control (vehicle) MCD group. Lowest mast 
cell numbers were observed in the low CBG treatment group.
Figure Two.  Results from the FcɛR1/TGFβ1 Immunofluorescence. Liver samples were from male mice. 
Red indicates FcɛR1 positive staining, or presence of mast cells. Green indicates TGFβ1 positive staining. 
Arrows point to colocalization, indicating presence of mast cell activity. 
Acknowledgments. 
Thank you to Dr. Han and Nouf who helped me greatly with this research, and
thank you to Michael and Brexton for helping me navigate the lab. 
Selected references. da Silva, Elaine Zayas Marcelino, Jamur, M. C., & Oliver, C. (2014). Mast cell function: A new vision of an old cell. Los Angeles, CA: SAGE Publications. Galli, S. J., & Nakae, S. (2003). Mast cells to the defense. Nature Immunology, 4(12), 1160-1162. Tsai, M., Nakae, S., & Galli, S. J. (2005). Mast cells in the development of adaptive 
immune responses. Nature Immunology, 6(2), 135-142. Sanyal, A. J. (2011). NASH: A global health problem. Hepatology Research, 41(7), 670-674. Oseini, A. M., & Sanyal, A. J. (2017). Therapies in non‐alcoholic steatohepatitis (NASH). Liver International, 37(Suppl 1), 97-103. Wree, A., Broderick, L., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2013). From NAFLD to NASH to cirrhosis-new 
insights into disease mechanisms. Nature Reviews.Gastroenterology & Hepatology, 10(11), 627-636. Eguchi, S., Hidaka, M., Kugiyama, T., Soyama, A., Hara, T., Nagakawa, K., . . . Kanetaka, K. (2021). Changes in the role and mode of liver resection for hepatocellular carcinoma over 20 years: A single-center analysis. World Journal of Surgery, 45(4), 1152-1158. Lewandowska, E. A., Wosiak, A., 
Zielinski, A., Brzezinski, P., Strzelczyk, J., Szymanski, D., & Kobos, J. (2020). Role of mast cells in the pathogenesis of liver fibrosis in nonalcoholic fatty liver disease. Polish Journal of Pathology, 71(1), 38-45. Lombardo, J., Broadwater, D., Collins, R., Cebe, K., Brady, R., & Harrison, S. (2018). Hepatic mast cell concentration directly correlates to stage of fibrosis in NASH. Human Pathology, 86, 129-
135. Borrelli, F., Fasolino, I., Romano, B., Capasso, R., Maiello, F., Coppola, D., Orlando, P., Battista, G., Pagano, E., Di Marzo, V., . Izzo, A. A. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology, 85(9), 1306-1316. Navarro, G., Varani, K., Reyes-Resina, I., Sánchez de Medina, V., Rivas-Santisteban, 
R., Sánchez-Carnerero Callado, C., Vincenzi, F., Casano, S., Ferreiro-Vera, C., Canela, E. I., Borea, P. A., Nadal, X., & Franco, R. (2018). Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1-CB2 Heteroreceptor Complexes. Frontiers in pharmacology, 9, 632. 
Background Information 
Mast Cell Immunofluorescence 
Results & Conclusion 
• CAE staining shows there are no mast cells 
present in CRT groups
• Mast cells appear in larger number in the 
control MCD group
• There are a lower number of mast cells in the 
experimental group treated with low CBG 
• Visual observation shows lower levels of 
adipose, supporting theory of NASH reversal 
• FcɛR1/TGFβ1 Immunofluorescence shows low 
mast cell numbers with low CBG treatment, 
and higher numbers with no treatment 
• Immunofluorescence results aligns with CAE 
staining results 
• Treatment with low CBG decreases mast cell 
immune response 
Future Directions
• Repeat study with larger sample group
• Further exploration of CBG’s role in 
potential NASH reversal 
• Explore potential off-target effects of CBG 
throughout body and other long-term 
effects of usage  
• Mast cells are immune cells that interact with any 
antigens, allergens, or pathogens, releasing 
mediators that regulate inflammation, smooth 
muscle contraction, vascular permeability, and  
initiate proliferation of epithelial cells and fibroblasts. 
• Non-alcoholic fatty liver disease (NAFLD) is the 
accumulation of fat in pathological amounts 
unrelated to alcohol consumption due to excess fatty 
acids and sugars in and individual's diet. 
• Non-alcoholic steatohepatitis (NASH) is the advances 
stage of NAFLD characterized by cell injury and 
fibrosis, which can lead to cirrhosis. 
• Multiple studies have found that mast cell numbers 
correlate directly to levels of fibrosis, as they are 
mediators to inflammation. 
• Cannabigerol (CBG) is a cannabinoid that is being 
researched as a medical treatment that acts as a 
regulator of endocannabinoid receptors CB1 and CB2, 



















• 7-8 week-old C57BL/6 mice were fed a control (CTR) diet 
or the MCD diet for 3 weeks
• CBG treatment was injected for 2 additional weeks while 
fed the same diets 
• Dosages: High CBG (24.6 mg/Kg/day), Low CBG (2.46 
mg/Kg/day)  
